
Halifax, Nova Scotia – December 24, 2024 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today, on December 24, 2024, the

Halifax, Nova Scotia, 13 August, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces it will conduct full clinical trials for its unique Multiplo® Complete

Halifax, Nova Scotia, March 13, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a Canadian patent (number 2,949,634) for its new

Halifax, Nova Scotia,1 February, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) is pleased to provide an update on the ongoing review process by Health Canada.

Halifax, Nova Scotia, 13 December, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR). MedMira Inc. proudly announces today the successful attainment of 510(k) clearance for

Corporate UpdateThroughout the reporting period, the Company achieved significant milestones in its pursuit of FDA and Health Canada approvals for a range of products. A

Halifax, Nova Scotia, 27 September, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its progress to achieve regulatory approval in Canada

MedMira has been notified that the Company has successfully defended its claim on its submitted trademarks. VYRAU.S. Serial Number: 90407022 BYRAU.S. Serial Number:
Contacts Investor Relations
For more information about MedMira or inquiries related to Investor Relations, please contact us. Our Investor relations team will get back to you immediately.
Corporate Headquarters
155 Chain Lake Drive, Suite 1
Halifax, Nova Scotia B3S 1B3
Canada
Phone: 902 450 1588
T/F. 877 633 6372
E-Mail: ir@medmira.com